RP Cure Tracker

Trials / NCT00559234

Potential Research Participants for Future Studies of Inherited Eye Diseases

Completed Observational Natural history / observational

Sponsor
National Eye Institute (NEI)
Treatment
Not listed
Gene
Not stated
Conditions
Cataract, Glaucoma, Retinitis Pigmentosa, Macular Degeneration, Strabismus
Ages
Any to no upper limit
Enrollment
400 participants
Started
2007-11-09
Main results expected
Not stated
Results posted
Not yet
Record last updated
2017-07-02

What the study is testing

This study will evaluate potential candidates for future clinical research studies related to diagnosed or undiagnosed genetic eye disorders or diseases. It will not test any new treatments, but it may arrange for standard treatments for existing eye disorders. The purpose of the study is to train eye doctors and medical researchers at the National Institutes of Health in appropriate methods and procedures for treating patients with genetic eye diseases, and to expand the pool of possible participants for future research studies and trials on eye health.

Volunteers for this study may be adults and minor children who have been diagnosed with or are at risk for having a genetic eye disease. Candidates may not have any other medical conditions that would interfere with the researchers' ability to perform the examinations and procedures required for this study.

Participants will give a complete medical and family history and undergo a series of tests and procedures as part of this research study. The procedures include a full eye examination and vision testing, electrooculography and an electroretinogram to examine the function of the retina, and flourescein angiography to provide information on the flow of blood in the participant's eyes. Participants will provide research material for further studies by giving a blood sample to be held for genetic testing and analysis, and adult participants will also undergo a skin biopsy to provide cell tissue for additional research material. At each clinic visit, participants will receive treatment for their genetic eye disease as needed, including medications or surgical procedures. Participants may remain a part of this study for up to three years.

Where it runs

United States (1)

Open on ClinicalTrials.gov for contacts and eligibility